GCN2 Modulator Compounds for Selective Stress Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective modulation of the General Control Nondepressible 2 (GCN2) kinase, which is involved in various cellular responses to stress and diseases such as cancer and neurodegenerative conditions, limiting therapeutic options for these conditions.
Innovation Solution
Development of novel compounds that act as GCN2 modulators, including inhibitors and agonists, to regulate GCN2 activity and provide therapeutic strategies for diseases involving GCN2, such as cancer and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment options are limited, but effective modulation of the GCN2 pathway is not achieved
Solution Approach 1:
The patent segments the GCN2 pathway modulation into distinct compound classes with different mechanisms of action (inhibitors, agonists, modulators), allowing for targeted therapeutic strategies for different diseases. This segmentation enables selective intervention in the GCN2 pathway while preserving other cellular functions.
Solution Approach 2:
The patent employs parameter changes by developing compounds with varying degrees of GCN2 pathway modulation (partial agonists, partial inhibitors, selective modulators). This allows for fine-tuning of the therapeutic effect to match the specific disease state, whether GCN2 is overactive or underactive.
2Ease of manufacture
If GCN2 pathway is modulated, then therapeutic strategies for amino acid deficiencies are improved, but disease progression reduction requires enhanced treatment efficacy
Solution Approach 1:
The patent uses GCN2 pathway modulators as intermediary compounds that mediate between amino acid deficiency states and cellular response. These compounds act as intermediaries to restore balanced protein synthesis and amino acid metabolism without directly supplying amino acids or completely blocking GCN2 function.
Solution Approach 2:
The patent develops composite therapeutic approaches by combining GCN2 pathway modulators with other therapeutic agents (amino acid supplements, protein synthesis inhibitors, disease-specific treatments). This composite strategy addresses multiple aspects of disease pathology simultaneously for enhanced efficacy.
Data Source
AI summary
The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein X, Y, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with General Control Nondepressible 2 (GCN2).